• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form F-1/A filed by Akanda Corp.

    9/29/25 1:28:44 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $AKAN alert in real time by email
    F-1/A 1 ea0258803-f1a1_akanda.htm AMENDMENT NO. 1 TO FORM F-1

    As filed with the Securities and Exchange Commission on September 29, 2025

    Registration No. 333-290367

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    AMENDMENT NO.1

    TO

     

    FORM F-1
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

    Akanda Corp.
    (Exact name of Registrant as specified in its charter)

     

    Ontario, Canada   2833   Not Applicable
    (State or other jurisdiction of
    incorporation or organization)
      (Primary Standard Industrial
    Classification Code Number)
      (I.R.S. Employer
    Identification No.)

     

    Akanda Corp.
    c/o Gowling WLG (Canada) LLP

    100 King St. W, Suite 1600

    Toronto, ON M5X 1G5, Canada
    Tel: +1 (416) 862-7525
    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

     

    C T Corporation System
    1015 15th Street N.W., Suite 1000
    Washington, D.C., 20005
    Tel: +1 (866) 925-9916
    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    With copies to:

     

    Stephen E. Fox

    Ruskin Moscou Faltischek, PC

    1424 RXR Plaza

    East Tower, 15th Floor

    Uniondale, New York 11576

    Tel: +1 (516) 663-6600

      Sharagim Habibi
    Gowling WLG(Canada) LLP
    1600, 421 7th Avenue SW, Calgary
    Alberta, T2p 4K9, Canada
    Tel: +1 (403) 298-1000
      David E. Danovitch
    Joseph E. Segilia
    Sullivan & Worcester LLP
    1251 Avenue of the Americas
    New York, NY 10020
    Tel: +1 (212) 660-3027

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

     

    Emerging Growth Company ☒

     

    If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

    †The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

     

     

     

     

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 6. Indemnification of Directors and Officers.

     

    In accordance with the Business Corporations Act (Ontario) and pursuant to the bylaws of the Company (the “Bylaws”), subject to certain conditions, the Company shall, to the maximum extent permitted by law, indemnify a director or officer, a former director or officer, or another individual who acts or acted at the Company’s request as a director or officer, or an individual acting in a similar capacity, of another entity, against all costs, charges and expenses, including any amount paid to settle an action or satisfy a judgment, reasonably incurred by the individual in respect of any civil, criminal, administrative, investigative or other proceeding in which the individual is involved because of that association with the Company or other entity. We shall advance monies to a director, officer or other individual for costs, charges and expenses reasonably incurred in connection with such a proceeding; provided that such individual shall repay the moneys if the individual does not fulfill the conditions described below or is not successful on the merits in their defense of the action or proceeding. Indemnification is prohibited unless the individual:

     

    ●Acted honestly and in good faith with a view to our best interests;

     

    ●In the case of a criminal or administration action or proceeding enforced by a monetary penalty, had reasonable grounds to believe the conduct was lawful; and

     

    ●Was not judged by a court or other competent authority to have committed any fault or omitted to do anything that the individual ought to have done.

     

    We also entered into indemnification agreements with each of our executive officers and directors. The indemnification agreements provide the indemnitees with contractual rights to indemnification, and expense advancement and reimbursement, to the fullest extent permitted under Ontario law.

     

    Item 7. Recent Sales of Unregistered Securities.

     

    Since January 1, 2022, we have issued and sold the securities described below without registering the securities under the Securities Act. The below described securities reflect the number of shares and prices as of the transaction date, and do not reflect any subsequent reverse stock splits.

     

      ● On March 14, 2022, the Company issued 348 Common Shares to the Akanda Bokamoso Empowerment Trust. The share based payment to the Akanda Bokamoso Empowerment Trust is a social development initiative of the Company and its beneficiaries are the employees of subsidiaries within the group.

     

    II-1

     

     

      ● On March 15, 2022, the Company issued 658 Common Shares to Halo at a price of $10,000 each to settle the principal amount of $6,559,294 plus accrued interest $23,686 owing to Halo in terms of a convertible debenture agreement, which totaled $6,582,980 at the time of conversion. The conversion of the debt owing was triggered by the Company’ initial public offering under the terms of the convertible debenture agreement.

     

      ● On April 20, 2022, we issued 760 Common Shares as consideration to The Flowr Corporation in connection with the Share Purchase Agreement, dated April 20, 2022, whereby our wholly owned subsidiary, Cannahealth, acquired all of the ordinary shares of Holigen Limited. The Common Shares were issued pursuant to Regulation S of the Securities Act.

     

      ● On October 26, 2022, we issued 240 restricted stock units to our former CEO, Tejinder Virk. The units were issued pursuant to our 2021 Equity Incentive Plan and vested immediately.

     

      ● On November 1, 2022, we issued 88 restricted stock units to Dr. Akkar-Schenki in connection with her resignation as President of the Company. The units were issued pursuant to our 2021 Equity Incentive Plan and vested immediately.

     

      ● On August 14, 2023, we issued 2,328 Common Shares to Halo in full satisfaction of the remaining outstanding balance of a promissory note payable to Halo;

     

      ● On October 11, 2023, we issued 3,519 Common Shares to 1107385 B.C. Ltd. as the first option payment pursuant to the Amended and Restated Option to Purchase Agreement dated September 22, 2023. The agreement is in connection to our acquisition of the right to develop a Canadian farming property in British Columbia, including farming land and related operations and licenses.

      

      ● In May 2024, we issued an aggregate of 60,251 Common Shares to certain of our consultants for services rendered.

     

      ● In September 2025, we issued an aggregate of 144,930 Class A Special Common Shares to the former shareholders of First Towers.

     

    The issuances of the above securities were deemed to be exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder, as transactions by an issuer not involving any public offering, or were issued in reliance upon Regulation S of the Securities Act, to an investor who is an “accredited investor,” as such term is defined in Rule 501(a) under the Securities Act, in an offshore transaction (as defined in Rule 902 under Regulation S of the Securities Act), based upon representations made by such investor.

     

    II-2

     

     

    Item 8. Exhibits and Financial Statements Schedule

     

    (10) The following exhibits are filed as part of this Registration Statement and are numbered in accordance with Item 601 of Regulation S-K:

     

            Incorporated by Reference
    Exhibit   Description   Schedule/
    Form
      File
    Number
      Exhibit   File Date
    2.1   Share Exchange Agreement dated as of March 5, 2025, among Akanda Corp., First Towers & Fiber Corp., and the other signatories thereto   6-K   001-41324   99.1   3/10/25
                         
    2.2   Second Amendment to Share Exchange Agreement dated as of August 19, 2025, between Akanda Corp. and First Towers & Fiber Corp., individually and on behalf of its shareholders   6-K   001-41324   10.1   8/22/25
                         
    3.1   Articles of Incorporation of Akanda Corp., dated July 16, 2021.   F-1   001-41324   3.1   2/14/22
                         
    3.2   Articles of Amendment of Akanda Corp., dated August 30, 2021.   F-1   001-41324   3.2   2/14/22
                         
    3.3   Articles of Amendment of Akanda Corp., dated March 8, 2023.   6-K   000-41324   99.2   3/8/23
                         
    3.4   Articles and Certificate of Amendment of Akanda Corp. dated May 23, 2024   6-K   001-41324   99.2   5/23/24
                         
    3.5   Articles and Certificate of Amendment of Akanda Corp. dated August 22, 2025   6-K   001-41324   99.2   8/22/25
                         
    3.6   Bylaws of Akanda Corp., dated July 16, 2021.   F-1   001-41324   3.3   2/14/22
                         
    5.1*   Opinion of Gowling WLG (Canada) LLP                
                         
    8.1*   Opinion of Gowling WLG (Canada) LLP as to Canadian tax matters (included in Exhibit 5.1)                
                         
    10.1+   Stock Option Plan of Akanda Corp.   F-1   001-41324   10.1   2/14/22
                         
    10.2+   Form of Indemnity Agreement with directors and executive officers.   F-1   001-41324   10.8   2/14/22
                         
    10.3#   Lock Up Agreement with Chris Cooper                
                         
    10.4#   Lock Up Agreement with Francisco Juarez                
                         
    10.5   Non-Competition Agreement dated April 21, 2022.   6-K   001-41324   10.3   4/27/22
                         
    10.6   Form of Independent Contractor Agreement between Akanda Corp. and Kiranjit Sidhu   F-1   333-277182   10.21   2/20/24
                         
    10.7   Consulting Agreement with IR Agency LLC   6-K   001-41324   10.1   3/28/24
                         
    10.8+   2024 Equity Incentive Plan   20-F   001-41325   4.31   5/1/24
                         
    10.9   Form of Securities Purchase Agreement   6-K   001-41325   1.1   5/20/24
                         
    10.10   Registration Rights Agreement dated August 19, 2025   6-K   001-41324   10.2   8/22/25

     

    II-3

     

     

            Incorporated by Reference
    Exhibit   Description   Schedule/
    Form
      File
    Number
      Exhibit   File Date
    10.11   Debt Settlement Agreement with PGC Finco Inc.   6-K   001-41324   10.3   8/22/25
                         
    10.12   Debt Settlement Agreement with Dunstan Holdings Ltd.   6-K   001-41324   10.4   8/22/25
                         
    10.13   Convertible Promissory Note with PGC Finco Inc.   6-K   001-41324   10.5   8/22/25
                         
    10.14   Convertible Promissory Note with Dunstan Holdings Ltd.   6-K   001-41324   10.6   8/22/25
                         
    10.15   Promissory Note with 1353744 B.C. Ltd.   6-K   001-41324   10.7   8/22/25
                         
    10.16   General Security Agreement in favor of 1353744 B.C. Ltd.   6-K   001-41324   10.8   8/22/25
                         
    10.17   Form of Securities Purchase Agreement dated September 11, 2025   6-K   001-41325   10.1   9/16/25
                         
    10.18   Form of Convertible Promissory Note   6-K   001-41324   10.2   9/16/25
                         
    10.19   Form of Registration Rights Agreement   6-K   001-41324   10.3   9/16/25
                         
    10.20*   Consulting Agreement with IR Agency LLC                
                         
    10.21   Amendment No. 1 to Option Purchase dated September 24, 2025   6-K   001-41324   10.1   9/26/2025
                         
    14.1   Code of Business Conduct and Ethics of Akanda Corp.   F-1   001-41324   14.1   2/14/22
                         
    14.2   Whistleblower Policy of Akanda Corp.   F-1   001-41324   14.2   2/14/22
                         
    14.3   Related Party Transactions Policy of Akanda Corp.   F-1   001-41324   14.3   2/14/22
                         
    21.1#   List of Significant Subsidiaries of Akanda Corp.                
                         
    23.1*   Consent of Gowling WLG (Canada) LLP (included in Exhibit 5.1).                
                         
    23.2#   Consent of Green Growth CPAs, independent registered public accounting firm.                
                         
    23.3#   Consent of Bush & Associates CPA LLC, independent registered public accounting firm                
                         
    24.1#   Power of Attorney (included on the signature page to this registration statement)                
                         
    101.INS#   Inline XBRL Instance Document.                
                         
    101.CAL#   Inline XBRL Taxonomy Extension Calculation Linkbase Document.                
                         
    101.SCH#   Inline XBRL Taxonomy Extension Schema Document.                
                         
    101.DEF#   Inline XBRL Taxonomy Extension Definition Linkbase Document.                
                         
    101.LAB#   Inline XBRL Taxonomy Extension Labels Linkbase Document.                
                         
    101.PRE#   Inline XBRL Taxonomy Extension Presentation Linkbase Document.                
                         
    104#   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).                
                         
    107#   Filing Fee Table                

     

     

      * Filed herewith.
    +Indicates management contract or compensatory plan.
      # Previously Filed.

     

    II-4

     

     

    Item 9. Undertakings.

     

    (a) The undersigned hereby undertakes:

     

    (1) to file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) that, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    (2) that for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof;

     

    (3) to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering;

     

    (4) to file a post-effective amendment to the registration statement to include any financial statements required by “Item 8.A. of Form 20-F” at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Securities Act need not be furnished; provided, that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements; and

     

    II-5

     

     

    (5) that, for the purpose of determining liability under the Securities Act to any purchaser:

     

    (i) if the registrant is relying on Rule 430B:

     

    (A) each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

     

    (B) each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or

     

    (ii) if the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

     

    (b) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    (c) The undersigned hereby undertakes:

     

    (1) that for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and

     

    (2) for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    II-6

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Boca Raton, FL, USA on September 26, 2025.

     

      Akanda Corp.

     

      By: /s/ Katie Field
        Name:  Katie Field
        Title: Interim Chief Executive Officer and
    Executive Director

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    *   Date: September 26, 2025
    Name:  Katie Field    
    Title: Interim Chief Executive Officer
    and Executive Director
       
    (Principal Executive Officer)    
         
    *   Date: September 26, 2025
    Name: Gurcharn Deol    
    Title: Chief Financial Officer    
    (Principal Financial Officer and Principal Accounting Officer)    
         
    *   Date: September 26, 2025
    Name: Christopher Cooper    
    Title: Director    
         
    *   Date: September 26, 2025
    Name: Jatinder Dhaliwal    
    Title: Director    
         
    *   Date: September 26, 2025
    Name: David Jenkins    
    Title: Director    
         
    *   Date: September 26, 2025
    Name: Usama Chaudhry    
    Title: Director    

     

    * Katie Field, pursuant to Powers of Attorney (executed by each of the officers and directors listed above and indicated as signed above, and filed with the Securities and Exchange Commission), by signing her name hereto does hereby sign and execute this Amendment to the Registration Statement on behalf of each of the persons referenced above.

     

    By: /s/ Katie Field   September 26, 2025
      Katie Field    
      Attorney-in-fact    

     

    II-7

     

     

    Signature of Authorized U.S. Representative of Registrant

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Akanda Corp., has signed this registration statement in the city of Boca Raton, FL, USA, on September 26, 2025.

     

      Authorized U.S. Representative

     

      By: /s/ Katie Field
        Name: Katie Field

     

     

    II-8

     

     

    Get the next $AKAN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AKAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akanda Discusses Altán Redes $7 Billion Project

    Unprecedented Scale and Investment to Connect MexicoToronto, Ontario--(Newsfile Corp. - October 1, 2025) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") and its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"), expands on the size and scale of Mexico's telecommunications infrastructure project, under the Red Compartida initiative. Altán Redes is undertaking one of the largest telecommunications undertakings in Mexico's history. The mission: to close the digital divide by building a wholesale LTE/4G (and progressively 5G-ready) network that will reach the vast majority of the Mexican population. As a preferred contractor of Altán Redes, every tower that FTF builds is expected

    10/1/25 8:00:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Akanda Among the Leaders of Deployment in Mexico's Largest Telecommunication Infrastructure Project

    Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Akanda Corp. (NASDAQ:AKAN) ("Akanda") is pleased to report on the progress of its 100% owned subsidiary First Towers & Fiber Corp. ("FTF" or the "Company"). FTF, a leader in telecommunications infrastructure in Mexico, today announced its continued commitment to increase data connectivity as a preferred contractor in Mexico's largest telecommunications infrastructure public / private project, managed by Altan Redes and CFE Telecomunicaciones. With 30 cellular towers already deployed and generating revenue throughout Mexico, FTF brings proven expertise and operational capacity to the project. The Company expects to play a key role in

    9/30/25 4:15:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Univest Securities, LLC Announces Closing of $5 Million Underwritten Public Offering for its Client Akanda Corp. (NASDAQ: AKAN)

    New York, March 27, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of underwritten public offering (the "Offering") of 3,087,443 common stock priced at $0.1217 per share, with pre-funded warrants exercisable for 37,997,190 shares with respect to the underwritten public offering for its client Akanda Corp. (NASDAQ:AKAN) ("Akanda" or the "Company"), an international medical cannabis company. Under the terms of the securities purchase agreement, the Company has agreed to sell to the institutional investors a total of 3,087,443 sh

    3/27/24 4:45:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    SEC Filings

    View All

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    10/10/25 2:00:26 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Akanda Corp.

    6-K - AKANDA CORP. (0001888014) (Filer)

    10/9/25 5:15:02 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B3 filed by Akanda Corp.

    424B3 - AKANDA CORP. (0001888014) (Filer)

    10/1/25 1:35:41 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Leadership Updates

    Live Leadership Updates

    View All

    Halo Collective Announces Change of Auditors and Failure to File Cease Trade Order

    Toronto, Ontario--(Newsfile Corp. - June 22, 2023) - Halo Collective Inc. (NEO: HALO) (OTCQB:HCANF) (FSE: A9K0) ("Halo" or the "Company") announces today that it has changed its auditor (the "Change of Auditor") from Macias Gini & O'Connell LLP (the "Former Auditor") to GreenGrowth CPAs (the "Successor Auditor"). The Former Auditor resigned effective June 19, 2023, and the Company's board of directors, upon the audit committee's recommendation, appointed the Successor Auditor to fill the resulting vacancy until the close of the next annual meeting of the Company's shareholders.There was no modified opinion, or other opinion, issued by the Former Auditor in connection with its audit of the Co

    6/22/23 1:06:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Canmart Ends CEO Service Agreement; Akanda Approves Appointment of Director

    International medical cannabis platform company Akanda Corp. ("Akanda" or the "Company") (NASDAQ:AKAN) today announced its subsidiary Canmart Ltd. brought Tejinder Virk's Service Agreement dated June 2, 2021 (the "Service Agreement") to an immediate end with effect from February 13th, 2023. As disclosed on February 7th, 2023, the Company disclosed Mr. Virk's attempt to end the Service Agreement without providing the requisite period of notice required under the Service Agreement, his interpretation of the Service Agreement, and allegations of Breach of Contract. On February 13th, 2023, the Company informed Mr. Virk that it had reached the conclusion that it has a right to bring the Service

    2/16/23 5:05:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    /R E P E A T -- Halo Collective Appoints Katie Field as Chairman of the Board/

    TORONTO, Aug. 12, 2022 /PRNewswire/ -  Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced the appointment of Katie Field, Chief Executive Officer of Halo, to Chairman of the board of directors of the Company (the "Board"), effective immediately. Current Chairman Ryan Kunkel has resigned from the Board to focus on other professional endeavors. To the knowledge of the Company, Ms. Field is the second woman to serve as Chairman and CEO of a publicly traded cannabis company, the first being Kim Rivers of Trulieve (CSE:TRUL). Ca

    8/12/22 8:00:00 AM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Financials

    Live finance-specific insights

    View All

    Halo Collective Completes Acquisition of Premium Indoor Grow and Distribution Hub in Portland, Oregon

    TORONTO, Sept. 22, 2022 /PRNewswire/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced, further to its press release dated August 27, 2021, that it has completed the acquisition of all of the substantial assets of three operating entities doing business as Pistil Point in Oregon which collectively hold multiple cannabis licenses. With this transaction, Halo now has full ownership of a range of indoor and outdoor cultivation, manufacturing, and distributions assets, along with an expanded library of genetics that is expected to allow the Company to continue to execute its vertically integrated strategy in Oregon with enhanced compet

    9/22/22 5:00:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Halo Collective Announces Westwood Dispensary Completion, Local Inspections Passed, and Planned Opening for Second Budega™ in California

    TORONTO, April 12, 2022 /PRNewswire/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced that its Budega Westwood Dispensary passed its Los Angeles inspection and is expected to open within 30 days. The Budega Westwood location is perfectly located nestled in between Westwood to the west and Beverly Hills to the east, right off of one of LA's most traveled and famous thoroughfares for locals and visitors, the Santa Monica Boulevard (10461 Santa Monica Blvd) and within two miles of the University of Los Angeles California campus. The facility is leased and near complete with renovations of its approximately 1,500 square foot prime retail

    4/12/22 4:40:00 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    $AKAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Akanda Corp. (Amendment)

    SC 13D/A - AKANDA CORP. (0001888014) (Subject)

    2/20/24 6:01:03 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Akanda Corp.

    SC 13D - AKANDA CORP. (0001888014) (Subject)

    2/20/24 5:17:13 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Akanda Corp. (Amendment)

    SC 13G/A - AKANDA CORP. (0001888014) (Subject)

    2/20/24 12:55:32 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care